Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea's Dong-A Regains Top Spot From Green Cross In Q2 Sales

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Dong-A Pharmaceutical regained South Korea's top sales spot in the second quarter from vaccine maker Green Cross and expects to continue its sales trend through the year

You may also be interested in...



LG Life Sciences' 2nd Quarter Sales Dampened By Strong Won, Tightened Regulatory Watch On Pharma

SEOUL - The ongoing appreciation of the Korean won vs. the U.S. dollar and a tighter government grip on pharmas to detect malpractices such as rebates - or kickbacks - in the local pharma industry adversely affected the second quarter earnings of LG Life Sciences

LG Life Sciences' 2nd Quarter Sales Dampened By Strong Won, Tightened Regulatory Watch On Pharma

SEOUL - The ongoing appreciation of the Korean won vs. the U.S. dollar and a tighter government grip on pharmas to detect malpractices such as rebates - or kickbacks - in the local pharma industry adversely affected the second quarter earnings of LG Life Sciences

South Korean Pharmas Clamber For Partnerships To Survive Rapidly Changing Environment

SEOUL - South Korea's local pharmas are clambering to tie the knot with multinationals and among themselves in what appears to be a "marriage of necessity" in a desperate attempt to survive a government crackdown on rebates, on which locals have long depended

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC075846

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel